Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy

to be Presented at the 2018 Annual Cure SMA Conference on June 16, 2018

SOUTH SAN FRANCISCO, Calif., June 08, 2018 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented in an oral presentation at the 2018 Annual Cure SMA Conference in Dallas on June 16, 2018.

Title: Update of CY 5021: A Phase 2 Clinical Trial of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator (FSTA), for the Potential Treatment of Spinal Muscular Atrophy

Press Release”